Barnett Mitchell J, Milavetz Gary, Kaboli Peter J
Center for Research in the Implementation of Innovative Strategies in Practice, Iowa City Veterans Administration Medical Center, University of Iowa, Iowa City, Iowa 52246, USA.
Pharmacotherapy. 2005 Nov;25(11):1550-9. doi: 10.1592/phco.2005.25.11.1550.
To determine whether an association exists between health care resource use and beta-blocker therapy in patients with asthma or chronic obstructive pulmonary disease (COPD), and to determine whether any significant differences exist between type of beta-blocker agent administered and resource use.
Retrospective cohort study.
Three Veterans Administration (VA) databases with information from hospitals and clinics in Iowa and Nebraska. Patients. A total of 8390 veterans with a diagnosis of asthma or COPD receiving treatment with a beta-blocker or another cardiovascular agent.
Clinic visits and hospital admissions for asthma or COPD that occurred in 2000-2001 were identified using electronic administrative data files. Analyses were adjusted for comorbidity and patient demographics. Mean patient age was 67 years, and 97% of the patients were men. In unadjusted analyses, patients taking beta-blockers had more hospital admissions, similar inpatient length of stay (LOS), and fewer outpatient clinic visits for asthma or COPD. In adjusted analyses, however, no difference was noted in the odds of hospital admission or in LOS, and patients had fewer clinic visits related to asthma or COPD. The hazard ratio for hospital admission for asthma or COPD during the observation year was similar for patients taking and not taking beta-blockers, and no difference was noted with selective versus nonselective beta-blockers. However, the hospital admission rate was lower with atenolol than metoprolol.
Patients taking beta-blockers did not have more hospital admissions or clinic visits for their asthma or COPD than patients not taking these agents. When clinically indicated, beta-blockers-especially atenolol-should be considered for patients with asthma or COPD.
确定哮喘或慢性阻塞性肺疾病(COPD)患者的医疗资源使用与β受体阻滞剂治疗之间是否存在关联,并确定所使用的β受体阻滞剂类型与资源使用之间是否存在显著差异。
回顾性队列研究。
来自爱荷华州和内布拉斯加州医院及诊所信息的三个退伍军人管理局(VA)数据库。患者。共有8390名诊断为哮喘或COPD并接受β受体阻滞剂或其他心血管药物治疗的退伍军人。
使用电子管理数据文件确定2000 - 2001年发生的哮喘或COPD门诊就诊和住院情况。分析针对合并症和患者人口统计学进行了调整。患者平均年龄为67岁,97%为男性。在未调整的分析中,服用β受体阻滞剂的患者因哮喘或COPD的住院次数更多,住院时间相似,门诊就诊次数更少。然而,在调整分析中,住院几率或住院时间并无差异,且患者与哮喘或COPD相关的门诊就诊次数更少。在观察年度,服用和未服用β受体阻滞剂的患者因哮喘或COPD住院的风险比相似,选择性与非选择性β受体阻滞剂之间未发现差异。然而,阿替洛尔的住院率低于美托洛尔。
服用β受体阻滞剂的哮喘或COPD患者的住院次数和门诊就诊次数并不比未服用这些药物的患者多。在有临床指征时,哮喘或COPD患者应考虑使用β受体阻滞剂,尤其是阿替洛尔。